Skip to main content

Table 1 Baseline characteristics of the patients at the time of completing the MISS questionnaire

From: High frequency of methotrexate intolerance in longstanding rheumatoid arthritis: using the methotrexate intolerance severity score (MISS)

Characteristics N = 120
Qualitative
 Female (%) 103 (85.8)
 MTX, subcutaneous (%) 66 (55)
 MTX dose (mg/week)
   < 10 (%) 1 (0.8)
  10.1–17.5 (%) 31 (25.8)
   > 17.5 (%) 88 (73.4)
 Leflunomide (%) 29 (24.2)
 Nonsteroidal anti-inflammatory drugs (%) 9 (7.5)
 Disease-modifying antirheumatic drugs – biological (%) 28 (23.3)
 Corticosteroids (%) 63 (52.5)
 Proton-pump inhibitors (%) 56 (46.7)
 Antiemetics (%) 1 (0.8)
 Folic acid
  No (%) 7 (5.8)
  5 mg/week (%) 92 (76.7)
  10 mg/week or more (%) 21 (17.5)
 DAS 28 moderate and high disease activity (%) 51 (45.5)
 Smoking
  No (%) 74 (62.2)
  Current smoker (%) 15 (12.6)
  Ex-smoker (%) 30 (25.2)
 Seropositive RA (%) 92 (76.7)
 Hypertension (%) 68 (56.7)
 Diabetes mellitus (%) 29 (24.2)
 Dyslipidemia (%) 36 (30.0)
 Hypothyroidism (%) 15 (12.5)
 Fibromyalgia (%) 10 (8.3)
 Gastroesophageal reflux disease (%) 12 (10.3)
 Antidepressant (%) 24 (20)
Quantitative
 Mean age, years (SD) 61 (12.5)
 Mean disease duration, years (SD) 16 (10.3)
 Mean MTX usage duration, years (SD) 7 (5.5)
 Mean dose of MTX, mg/week (SD) 20 (5.1)
 Mean DAS28 (SD) 3.25 (3.1)
  1. DAS 28 Disease activity score in 28 joints; MTX Methotrexate; SD Standard deviation